Compare VYNE & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYNE | HHS |
|---|---|---|
| Founded | 2003 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 21.2M |
| IPO Year | 2017 | 1994 |
| Metric | VYNE | HHS |
|---|---|---|
| Price | $0.61 | $2.37 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 210.0K | 3.1K |
| Earning Date | 05-07-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 97.35 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $159,570,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $2.31 |
| 52 Week High | $1.98 | $5.39 |
| Indicator | VYNE | HHS |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 30.60 |
| Support Level | $0.56 | $2.33 |
| Resistance Level | $0.75 | $3.03 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 47.34 | 22.22 |
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.